Compare STRA & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STRA | KARD |
|---|---|---|
| Founded | 2017 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 1996 | 2026 |
| Metric | STRA | KARD |
|---|---|---|
| Price | $82.39 | $14.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $96.67 | $42.25 |
| AVG Volume (30 Days) | 208.0K | ★ 638.3K |
| Earning Date | 11-05-2026 | 11-22-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | ★ 15.85 | N/A |
| EPS | ★ 3.19 | N/A |
| Revenue | ★ $997,137,000.00 | N/A |
| Revenue This Year | $2.51 | N/A |
| Revenue Next Year | $2.96 | N/A |
| P/E Ratio | $25.22 | ★ N/A |
| Revenue Growth | ★ 57.23 | N/A |
| 52 Week Low | $69.70 | $12.23 |
| 52 Week High | $89.73 | $27.00 |
| Indicator | STRA | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 57.63 | 36.32 |
| Support Level | $77.55 | $13.75 |
| Resistance Level | $85.36 | $22.81 |
| Average True Range (ATR) | 2.20 | 1.30 |
| MACD | 0.46 | -0.02 |
| Stochastic Oscillator | 94.72 | 34.46 |
Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.